GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Other Operating Expense
Switch to:

Biogen (MEX:BIIB) Other Operating Expense

: MXN10,029 Mil (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's Other Operating Expense for the three months ended in Mar. 2023 was MXN1,934 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2023 was MXN10,029 Mil.

Biogen's quarterly Other Operating Expense increased from Sep. 2022 (MXN2,048 Mil) to Dec. 2022 (MXN4,098 Mil) but then declined from Dec. 2022 (MXN4,098 Mil) to Mar. 2023 (MXN1,934 Mil).

Biogen's annual Other Operating Expense increased from Dec. 2020 (MXN13,879 Mil) to Dec. 2021 (MXN18,227 Mil) but then declined from Dec. 2021 (MXN18,227 Mil) to Dec. 2022 (MXN6,989 Mil).


Biogen Other Operating Expense Historical Data

The historical data trend for Biogen's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Operating Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,305.71 13,796.09 13,878.65 18,226.69 6,989.32

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Operating Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,003.52 1,949.43 2,047.71 4,098.06 1,934.08

Biogen Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN10,029 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Biogen's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines